TransLabs Expands Molecular Diagnostics and Cytogenetics Coding Expertise for Laboratory Clients

SACHSE, United States — November 21, 2026 — TransLabs, a company that provides lab billing and coding services exclusively to clinical, reference, and molecular diagnostic laboratories, today announced an expansion of its coding expertise in molecular diagnostics and cytogenetics, two technically complex disciplines in laboratory medicine where coding accuracy directly affects reimbursement.

The expansion comes as volumes of next-generation sequencing panels, FISH probe studies, microarray testing, and karyotyping continue to climb across hospital, reference, and specialty laboratories. As test menus in these areas grow, the coding and billing requirements attached to them have become more demanding. That added complexity places pressure on laboratory revenue cycle operations, particularly where a single test may involve multiple procedural components, varying levels of analytical complexity, and payer-specific documentation rules.

Payers have responded to the growth in molecular and cytogenetic testing by tightening tier-based molecular pathology coding rules, expanding prior authorization requirements, and increasing scrutiny of component versus global billing claims. According to TransLabs, this shift has left many laboratories exposed to denials and underpayment on their most technically demanding tests. Because these tests often carry higher per-claim values than routine laboratory testing, coding errors in these disciplines can have a measurable effect on a laboratory’s collections.

“Laboratories are innovating faster than the reimbursement system can keep up with, and that gap is where revenue quietly disappears,” said Nathan Hill, Operations Manager of TransLabs.

Jones said the company made a deliberate decision to go deeper into molecular diagnostics and cytogenetics so that its laboratory clients have a billing partner that understands the science behind each test in addition to the code on the claim. He noted that molecular and cytogenetic testing demand a level of coding precision that requires specialized knowledge of both laboratory procedures and payer policy.

Under the expanded initiative, TransLabs is adding coders certified specifically in cytogenetics karyotyping, FISH and microarray procedures, flow cytometry immunophenotyping, and molecular tier-based CPT assignment. These additions are intended to align coding staff expertise with the specific procedures that laboratories perform in these disciplines, so that claims reflect the test as performed, including the correct tier, component, and level of complexity.

The company has also updated its library of payer-specific edits and prior authorization requirements for high-complexity testing. The updated library is designed to account for differences in how individual payers handle molecular and cytogenetic claims, including variations in tier-based coding policy, component and global billing rules, and authorization requirements that apply before testing is performed or billed.

In addition, TransLabs is extending its denial-analytics reporting to flag recurring issues unique to molecular diagnostics and cytogenetics. Examples include probe configuration mismatches and specimen complexity misclassification, both of which can lead to denied or underpaid claims when not identified. The extended reporting is designed to surface these patterns before they affect a laboratory’s revenue cycle, giving laboratory clients visibility into discipline-specific issues rather than general denial trends alone.

The announcement reflects a broader industry pattern, as laboratory executives increasingly cite molecular and genetic test complexity as a significant driver of denials and delayed reimbursement. TransLabs said it will continue investing in specialty-specific coding education and payer policy tracking as testing technology continues to advance. The company indicated that ongoing education for its coding staff and continuous monitoring of payer policy changes are central to maintaining accuracy as new tests, probes, and sequencing panels enter laboratory menus.

The expanded capabilities apply to laboratories that run molecular diagnostics or cytogenetics testing menus, including hospital laboratories, reference laboratories, and specialty laboratories. The additions build on the lab billing and coding services TransLabs already provides to clinical, pathology, molecular diagnostic, toxicology, cytogenetics, genomics, and specialty laboratories across the United States, adding discipline-specific depth in areas where coding rules and payer requirements have grown more detailed.

With this expansion, TransLabs is focusing its specialty coding resources on the technical disciplines where laboratories face the greatest exposure to coding-related denials and underpayment. The combination of certified specialty coders, an updated payer edit and prior authorization library, and discipline-specific denial analytics is intended to support accurate claim submission for molecular and cytogenetic tests from the point of coding through reimbursement.

About TransLabs

TransLabs is a laboratory billing and revenue cycle management company built exclusively for clinical laboratories. The company specializes solely in laboratory revenue cycle management, serving clinical, pathology, molecular diagnostic, toxicology, cytogenetics, genomics, and specialty laboratories nationwide. TransLabs combines a compliance-first approach, automation, and dedicated account management, and works with laboratories of every size, from community hospital laboratories to large reference facilities.

Media Details

Contact Person: Nathan Hill
Company Name: TransLabs
Email: info@translabsbilling.com
Website: https://translabsbilling.com/

 

 

Distributed By: Pulsebulletin.com